Skip to main content

Table 1 Alemtuzumab in clinical trials

From: Novel agents for chronic lymphocytic leukemia

Study agents

Other agents

Disease

Dosage

Clinical trials

No Pts

Response

Reference

Alemtuzumab

 

High risk

30 mg

Phase II

93

CR:2%

[19]

ORR:33%

Alemtuzumab

Dexamethasone

Untreated

30 mg

Phase II

131

CR:19/4/3%

[20]

Relapsed

ORR:98/79/70%

Refractory

Alemtuzumab

Rituximab

High risk

30 mg

Phase I

13

CR:64%

[21]

 

PGG beta glucan

    

ORR:100%

 
  1. Abbreviations. ORR overall response rate, CR complete response rate.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us